Novartis scoops up rights to NASH drug
admin 4th May 2017 Uncategorised 0Novartis has exercised an option giving it global development and commercialisation rights to an experimental drug being developed by US biotech Conatus for nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
More: Novartis scoops up rights to NASH drug
Source: News